These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23144072)

  • 21. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and economic impact of a switch from high- to low-volume renal replacement therapy in patients with acute kidney injury.
    Paterson AL; Johnston AJ; Kingston D; Mahroof R
    Anaesthesia; 2014 Sep; 69(9):977-82. PubMed ID: 24888258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury.
    Schoenfelder T; Chen X; Bleß HH
    GMS Health Technol Assess; 2017; 13():Doc01. PubMed ID: 28326146
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis.
    Desai AA; Baras J; Berk BB; Nakajima A; Garber AM; Owens D; Chertow GM
    Arch Intern Med; 2008 Sep; 168(16):1761-7. PubMed ID: 18779463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of separated continuous renal replacement therapy systems versus intermittent hemodialysis in critically ill patients with acute kidney injury in a low-resource setting.
    Phongphithakchai A; Liabsuetrakul T; Boonsrirat U
    Artif Organs; 2023 Sep; 47(9):1522-1530. PubMed ID: 37120798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of a short stay admission programme for breast cancer surgery.
    de Kok M; Dirksen CD; Kessels AG; van der Weijden T; van de Velde CJ; Roukema JA; Bell AV; van der Ent FW; von Meyenfeldt MF
    Acta Oncol; 2010 Apr; 49(3):338-46. PubMed ID: 20397768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic evaluation of early versus delayed operative treatment in patients with closed tibial shaft fractures.
    Sprague S; Bhandari M
    Arch Orthop Trauma Surg; 2002 Jul; 122(6):315-23. PubMed ID: 12136294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective.
    Laukkanen A; Emaus L; Pettilä V; Kaukonen KM
    Intensive Care Med; 2013 Mar; 39(3):406-13. PubMed ID: 23184040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care.
    Korkeila M; Ruokonen E; Takala J
    Intensive Care Med; 2000 Dec; 26(12):1824-31. PubMed ID: 11271091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome comparisons of intermittent and continuous therapies in acute kidney injury: what do they mean?
    Ronco C; Bagshaw SM; Gibney RT; Bellomo R
    Int J Artif Organs; 2008 Mar; 31(3):213-20. PubMed ID: 18373314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Acute Kidney Injury - Potentials to Improve AKI-Related Health Care Structure].
    Nusshag C; Obermann K; Weigand M; Schwenger V
    Dtsch Med Wochenschr; 2017 Apr; 142(7):534-540. PubMed ID: 28388752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Analysis of Renal Replacement Therapy Modality in Acute Kidney Injury Patients With Fluid Overload.
    Ethgen O; Murugan R; Echeverri J; Blackowicz M; Harenski K; Ostermann M
    Crit Care Explor; 2023 Jun; 5(6):e0921. PubMed ID: 37637357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness achieved through changing the composition of renal replacement therapy in Japan.
    Shimizu U; Saito S; Lings Y; Iino N; Kazama JJ; Akazawa K
    J Med Econ; 2012; 15(3):444-53. PubMed ID: 22250787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of cost-effectiveness analyses across the acute kidney injury landscape.
    Suh K; Kellum JA; Kane-Gill SL
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):571-578. PubMed ID: 33522323
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evidence-based renal replacement therapy--intermittent versus CRRT].
    Jörres A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2013 Mar; 48(2):108-13. PubMed ID: 23504467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute kidney injury, length of stay, and costs in patients hospitalized in the intensive care unit.
    Vandijck DM; Oeyen S; Decruyenaere JM; Annemans L; Hoste EA
    Acta Clin Belg; 2007; 62 Suppl 2():341-5. PubMed ID: 18283996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of the TherMax blood warmer during continuous renal replacement therapy.
    Blackowicz MJ; Bell M; Echeverri J; Harenski K; Broman ME
    PLoS One; 2022; 17(2):e0263054. PubMed ID: 35113881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.